our Thanks, revenue our our provide insights strategy, near-term some with Stephen. reiterate Today, I into commercial want drivers progress to and customers.
I on Slide will key X. highlight milestones.
Starting upcoming Finally, some
we what consistent this with of year. beginning focus commercial Our stated at the remains
We in delivering size both our revenue in this quarter. grew pipeline customer existing growth and from are pharma Orders manufacturing. quantity
double-digit in to the growth end revenues pipeline. our from Our intention decade annual of the through provide is existing
also the adding are new programs to business. prospects We long-term this customer secure of
for focused ligase the are they we securing existing Next, enzymes as RNA double-stranded our on progress through follow-on expected orders customers clinic. from
excitement new variants, indicates are performance time the to led manufacturing feedback which double-stranded reduced ligase our testing Continued they customers purification costs. and regarding promises superior seeing, outreach and has
adding a construct into and the capabilities demonstrate are Lab, desired Synthesis where of our customer's we Innovation platform. our we Synthesis siRNA Finally, programs ECO on ECO development focused manufacturing can synthesize
Moving X. to Slide
TIDES in We Europe on track X presentations are mid-November. for meeting exciting the at
superiority presentation specializing in siRNA. leading the our First, collaboration demonstrating RNA we poster in variants CDMO of of double-stranded manufacture have a with a Bachem, joint ligase the
wild-type have our will oral using ligase presentation various using we engineered comparing data on an versions. manufacturing versus Second, siRNA
variety with drug the synthesis of available emphasizing of customers' variety Third that meet will presentation commercially oral growing another enzymatic a our ways capabilities. in ability our Synthesis to demonstrates of approaches, using ECO a be needs a
top share drug commercial players. to the concrete and from results application siRNA customer further are the showcasing we real-world the a from seeing our of another technology with collaboration innovator, interest expect also major We
a I X:XX we Time attend be November investor news With will not aware our host blocks are be emerging Relations Eastern to can bit to webcast website.
On XX ECO the in we to We meeting Investor opportunity information meetings, Slide call Currently, it for our are used TIDES mind, are from focus market where are review intending and points related are an don't at that chemically. that relay on many Synthesis phosphate, challenging the call synthesized as key quatro a NQP, keep or The our the X, that on you and want webcast, building of on presentations. a for platform. this recap they to second access nucleotide available will track. in in p.m. process
terms at to near-term as great opportunity, provide them market process innovators they the need to quality, made becoming that the want reach drug platform is can of in this of have an a demand chemical building siRNA technical a more Like our comparable to large the NTP, important and approach in these the ligase for and the cost more process process.
Furthermore, even scale of sustainability scalability, ECO version and X, can blocks their enzymatic may our synthesis. in do This their all a materials Synthesis Slide process double-stranded future expand triphosphate, will for NQPs growing sustainable or understand support source efficiency, sufficient production.
On needs. simplified customers for also on platform use the reliable used that can know We we to what mRNA nucleotide at used the mRNA as building produce sustainably make approach. and fully of to progress enzymatic also a increasingly similar
short early the Lab Synthesis the tech development. gives a ability to sufficient facility.
In ECO It of to GMP scaling Innovation will on GLP-grade critical. for manufacture to also process production, before the quantities us so Our to specific focus support transfer term, partnerships is in us GMP material allows preclinical optimize optimization process we
are to and we tech towards support a clinical trials for scale-up We beyond. CDMO transfer GMP production a can customer's partnership a siRNA bulk working solidifying with where
ask, our scale-up partners The GMP the will enter answer believe directly value we own kilogram supply facility as is in GMP to is might trials. You We scale foreseeable rely for customers early establishing phase future? they there significant clinical no. on
examples look year. drug track EU the to XXth. established We sharing ECO longer TIDES the capture platform with on Synthesis on allowing for have over our Synthesis who revenue milestones product.
Shifting X. the to customer multiple at GMP, the us adoption to don't and to collaborations life ECO manufacturing Slide expect remain this to of customer to Innovation innovators November we the And on of hold the accelerate to smaller of path more briefly of We completion XXth of from end forward Lab to the by an
and will the increasing their Looking on material. to customers GLP-grade ahead using Lab Synthesis manufacturing Synthesis, number in through for our platform XXXX, of our ECO Innovation scale ECO building produce we siRNA concentrate
to Georgia of scale-up and Finally, year, call and we discuss presenting at let financial announce the our me next over year. the the TIDES key meetings in rest addition expect outlook sign to also turn for GMP both partnership.
With that, to a results to again
